Collectively, the current study revealed the efficacy of the newly synthesized N-(pyridin-2-yl)-4-(thiazolo[4,5-b]quinoxalin-2(3H)-ylideneamino) benzene-sulfonamide (4d) as down regulator to VEGFR-2 activity and a cytotoxic agent against HCC. The gene discussed is KDR; the disease is hepatocellular carcinoma.